IDEAYA Biosciences

Edit info

Founded: 2015

Location: South SF, CA

Employee range: 50 - 200

Clinical stage: Clin2

Therapy area: Uveal melanoma (partner: Pfizer)

Drug types: ONC

Lead product: Darovasertib

Funding: $201M stock Apr 2023; $86M stock Jul 2021; $57.5M IPO May 2019; $94M B Mar 2018; $46M A Apr 2016

ideayabio.com

linkedin.com

job board

Drug notes:

IDE397 Clin2 NSCLC, esophagogastric cancer, Clin1 solid tumors (partner: Amgen); IDE161 Clin1 breast, ovarian cancers; 4 add'l products RD cancer

About:

IDEAYA Biosciences is using synthetic lethality to design therapeutics for cancer. Synthetic lethality is a situation where inhibition of two genes together - but not each individually - results in cell death. IDEAYA is exploiting synthetic lethality interactions to identify a novel set of drug targets across different organisms and in human tumor cells. To achieve this, IDEAYA is using their DECIPHER Dual CRISPR Synthetic Lethality library with proprietary data and collaborations with the Broad Institute of Harvard and MIT. IDEAYA has a diverse pipeline of drugs in clinical stage development for a variety of solid tumors.